TrialBMC cancer2014

A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer.

Yun Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.